Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 2
2(40.0%)
5Total
N/A(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07299838Completed

Palopegteriparatide in Chronic Hypoparathyroidism

Role: collaborator

NCT07108517Not ApplicableRecruiting

A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth

Role: collaborator

NCT04508855Withdrawn

Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)

Role: collaborator

NCT00832234Phase 2Completed

Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

Role: collaborator

NCT01409551Not ApplicableCompleted

Video-assisted Hyperthermic Pleural Chemoperfusion vs Talc Pleurodesis for Refractory Malignant Pleural Effusions.

Role: lead

NCT01397045Not ApplicableCompleted

Fast Track Rehabilitation Following Video-assisted Lung Segmentectomy

Role: lead

NCT01301248Phase 2Unknown

Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck

Role: lead

All 7 trials loaded